Cannabis-associated psychosis: Neural substrate and clinical impact

R. M. Murray, A. Englund, A. Abi-Dargham, D. A. Lewis, M. Di Forti, C. Davies, M. Sherif, P. McGuire, D. C. D'Souza

Research output: Contribution to journalReview articlepeer-review

130 Citations (Scopus)


Prospective epidemiological studies have consistently demonstrated that cannabis use is associated with an increased subsequent risk of both psychotic symptoms and schizophrenia-like psychoses. Early onset of use, daily use of high-potency cannabis, and synthetic cannabinoids carry the greatest risk. The risk-increasing effects are not explained by shared genetic predisposition between schizophrenia and cannabis use. Experimental studies in healthy humans show that cannabis and its active ingredient, delta-9-tetrahydrocannabinol (THC), can produce transient, dose-dependent, psychotic symptoms, as well as an array of psychosis-relevant behavioral, cognitive and psychophysiological effects; the psychotogenic effects can be ameliorated by cannabidiol (CBD). Findings from structural imaging studies in cannabis users have been inconsistent but functional MRI studies have linked the psychotomimetic and cognitive effects of THC to activation in brain regions implicated in psychosis. Human PET studies have shown that acute administration of THC weakly releases dopamine in the striatum but that chronic users are characterised by low striatal dopamine. We are beginning to understand how cannabis use impacts on the endocannabinoid system but there is much still to learn about the biological mechanisms underlying how cannabis increases risk of psychosis.

Original languageEnglish
Pages (from-to)89-104
Number of pages16
Early online date17 Jun 2017
Publication statusE-pub ahead of print - 17 Jun 2017


  • Journal Article
  • Review


Dive into the research topics of 'Cannabis-associated psychosis: Neural substrate and clinical impact'. Together they form a unique fingerprint.

Cite this